Literature DB >> 7149708

Projections of a rebound in frequency of mental retardation from phenylketonuria.

H N Kirkman.   

Abstract

The present decade marks the end of a unique generation--when the public benefited from the prevention of mental retardation phenylketonuria (PKU) without having to deal fully with the problems which can be anticipated from the reproduction of successfully treated, phenylketonuric individuals. The dysgenic effect (increase in prevalence of the PKU gene) from this reproduction will have negligible influence on the frequency of mental retardation from PKU over the next few centuries. In contrast, a dysgenic effect from maternal PKU will cause a rebound in frequency of mental retardation within this decade. Failure of the PKU programs as a result of maternal PKU, could affect the public attitude toward programs for the study and prevention of mental retardation and genetic diseases. Minimizing and explaining the rebound in frequency of mental retardation will be a difficult but necessary task for workers in the field of mental retardation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149708     DOI: 10.1016/0270-3092(82)90023-6

Source DB:  PubMed          Journal:  Appl Res Ment Retard        ISSN: 0270-3092


  7 in total

Review 1.  Molecular genetics of phenylketonuria and its implications.

Authors:  H L Levy
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

2.  Maternal Phenylketonuria (MPKU).

Authors:  W E Schoonheyt; W B Hanley; J T Clarke; V Austin; D A Howe
Journal:  Can Fam Physician       Date:  1986-10       Impact factor: 3.275

3.  The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria.

Authors:  H H Kecskemethy; D Lobbregt; H L Levy
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

4.  Outcome implications of the International Maternal Phenylketonuria Collaborative Study (MPKUCS): 1994.

Authors:  R Koch; H Levy; W Hanley; R Matalon; B Rouse; F Trefz; F de la Cruz
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

5.  The International Collaborative Study on maternal phenylketonuria: organization, study design and description of the sample.

Authors:  E G Friedman; R Koch; C Azen; H Levy; W Hanley; R Matalon; B Rouse; F Trefz; F de la Cruz
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 6.  Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations.

Authors:  B J Rossiter; C T Caskey
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

7.  Psychosocial factors in maternal phenylketonuria: prevention of unplanned pregnancies.

Authors:  S E Waisbren; S Shiloh; P St James; H L Levy
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.